Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Subscribe To Our Newsletter & Stay Updated